Physician profile
Karin S Linthicum
NPI 1760550164
$3,806.13
in general payments reported to CMS, 2019-2025
26 companies · $71.23 in 2025
The $71.23 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $38.68 · 2021: $381 · 2022: $1,419 · 2023: $1,258 · 2024: $427 · 2025: $71.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.56 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $534.83 | 2019-2024 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $441.53 | 2019-2025 | |
| Genzyme Corporation | $326.30 | 2021-2023 | |
| Amgen INC. | $300.42 | 2019-2024 | Otezla |
| Pfizer INC. | $241.73 | 2019-2023 | |
| Leo Pharma INC. | $240.06 | 2019-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $220.46 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $169.35 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $153.05 | 2022-2024 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $86.26 | 2023-2024 | Zoryve |
| Almirall LLC | $76.39 | 2019-2021 | |
| Convatec INC. | $52.21 | 2023-2024 | |
| Incyte Corporation | $47.09 | 2022-2023 | Opzelura |
| Biofrontera INC. | $37.04 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $33.65 | 2022-2023 | Vtama |
| Galderma Laboratories, L.P. | $29.18 | 2023 | Oracea |
| Journey Medical Corporation | $29.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.50 | 2022 | |
| Ucb, INC. | $24.34 | 2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.44 | 2023 | Arazlo |
| Vyne Pharmaceuticals INC. | $21.03 | 2021 | |
| Organogenesis INC. | $20.74 | 2023 | Puraply |
| Janssen Biotech, INC. | $17.40 | 2022 | |
| Allergan, INC. | $17.20 | 2021 | |
| Epi Health, LLC | $16.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Linthicum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.